Influence of erythropoietin simulating agents and iron therapy on HbA1c

Completed

• Conditions: Diabetes mellitus/chronic kidney disease; Nutritional, Metabolic, Endocrine; Non-insulin-dependent diabetes mellitus

• Registration Number: ISRCTN52414847
• Lead Sponsor: Hull and East Yorkshire Hospitals NHS Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-05-12
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Patients with established chronic kidney disease (stage III - IV) (estimated glomerular filtration rate [eGFR] using Modification of Diet in Renal Disease [MDRD] 15 - 59 mL/min/1.73 m^2) who are to undergo iron and/or erythropoiesis stimulating agent (ESA) therapy
2. Patients who have established diabetes mellitus - both type I and II
3. Patients with no prior diagnosis of diabetes mellitus (control group)
4. Aged 18 to 80 years, either sex

Exclusion Criteria

1. Patients who not have renal failure (CKD stage I and II)
2. Patients who are unable or do not wish to give consent
3. Patients with currently investigated for potential blood loss
4. Patients with a haematological malignancy/haemolysis
5. Patients with known haemaglobinopathy
6. Patient with significant liver disease (prothrombin time [PT] greater than 16)
7. Patients with a diagnosis of myeloma
8. Patients with severe hyperparathyroidism (parathyroid hormone [PTH] greater than 800 picograms/ml)

Study & Design

• Study Type: Interventional
• Study Design: Not specified